CA3076094A1 - Mutated glycoprotein of vesicular stomatitis virus - Google Patents
Mutated glycoprotein of vesicular stomatitis virus Download PDFInfo
- Publication number
- CA3076094A1 CA3076094A1 CA3076094A CA3076094A CA3076094A1 CA 3076094 A1 CA3076094 A1 CA 3076094A1 CA 3076094 A CA3076094 A CA 3076094A CA 3076094 A CA3076094 A CA 3076094A CA 3076094 A1 CA3076094 A1 CA 3076094A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- amino acid
- protein
- vsv
- naturally occurring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000711975 Vesicular stomatitis virus Species 0.000 title description 141
- 108090000288 Glycoproteins Proteins 0.000 title description 40
- 102000003886 Glycoproteins Human genes 0.000 title description 40
- 150000001413 amino acids Chemical class 0.000 claims abstract description 197
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 192
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 187
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 68
- 210000004027 cell Anatomy 0.000 claims description 127
- 238000006467 substitution reaction Methods 0.000 claims description 76
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 31
- 102000005962 receptors Human genes 0.000 claims description 30
- 108020003175 receptors Proteins 0.000 claims description 30
- 241000700605 Viruses Species 0.000 claims description 25
- 238000003780 insertion Methods 0.000 claims description 18
- 230000037431 insertion Effects 0.000 claims description 18
- 239000012528 membrane Substances 0.000 claims description 16
- 230000034217 membrane fusion Effects 0.000 claims description 13
- 102000006240 membrane receptors Human genes 0.000 claims description 13
- 108020004084 membrane receptors Proteins 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 10
- 238000007792 addition Methods 0.000 claims description 9
- 238000012217 deletion Methods 0.000 claims description 8
- 230000037430 deletion Effects 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 150000002632 lipids Chemical class 0.000 claims description 8
- 230000008685 targeting Effects 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 230000001413 cellular effect Effects 0.000 claims description 6
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 description 205
- 235000018102 proteins Nutrition 0.000 description 154
- 108091006027 G proteins Proteins 0.000 description 80
- 102000030782 GTP binding Human genes 0.000 description 80
- 108091000058 GTP-Binding Proteins 0.000 description 80
- 108010001831 LDL receptors Proteins 0.000 description 50
- 102000000853 LDL receptors Human genes 0.000 description 47
- 238000002474 experimental method Methods 0.000 description 46
- 230000027455 binding Effects 0.000 description 35
- 238000009739 binding Methods 0.000 description 35
- 239000013598 vector Substances 0.000 description 27
- 239000005090 green fluorescent protein Substances 0.000 description 26
- 208000015181 infectious disease Diseases 0.000 description 20
- 102100039384 Huntingtin-associated protein 1 Human genes 0.000 description 19
- 101710140977 Huntingtin-associated protein 1 Proteins 0.000 description 19
- 230000004927 fusion Effects 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 14
- 102220485922 Putative uncharacterized protein DHRS4-AS1_K47A_mutation Human genes 0.000 description 13
- 102000007330 LDL Lipoproteins Human genes 0.000 description 12
- 108010007622 LDL Lipoproteins Proteins 0.000 description 12
- 230000003993 interaction Effects 0.000 description 12
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 10
- 238000002372 labelling Methods 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- 230000003612 virological effect Effects 0.000 description 10
- YURDCJXYOLERLO-LCYFTJDESA-N (2E)-5-methyl-2-phenylhex-2-enal Chemical compound CC(C)C\C=C(\C=O)C1=CC=CC=C1 YURDCJXYOLERLO-LCYFTJDESA-N 0.000 description 8
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 8
- 230000002378 acidificating effect Effects 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 102000005720 Glutathione transferase Human genes 0.000 description 6
- 108010070675 Glutathione transferase Proteins 0.000 description 6
- 102000010995 Pleckstrin homology domains Human genes 0.000 description 6
- 108050001185 Pleckstrin homology domains Proteins 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 238000000111 isothermal titration calorimetry Methods 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 101150082239 G gene Proteins 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 229960003180 glutathione Drugs 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 239000002105 nanoparticle Substances 0.000 description 5
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 235000011148 calcium chloride Nutrition 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000010415 tropism Effects 0.000 description 4
- 239000012103 Alexa Fluor 488 Substances 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000056303 Ferlin Human genes 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000006167 equilibration buffer Substances 0.000 description 3
- 210000001808 exosome Anatomy 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 230000000174 oncolytic effect Effects 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000002864 sequence alignment Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- -1 vesicle Substances 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- 108700011066 PreScission Protease Proteins 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108010046722 Thrombospondin 1 Proteins 0.000 description 2
- 102100036034 Thrombospondin-1 Human genes 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 241000711970 Vesiculovirus Species 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000002121 endocytic effect Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000000799 fusogenic effect Effects 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 210000002288 golgi apparatus Anatomy 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 108020001756 ligand binding domains Proteins 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 244000309459 oncolytic virus Species 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000005829 trimerization reaction Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- DLZKEQQWXODGGZ-KCJUWKMLSA-N 2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 DLZKEQQWXODGGZ-KCJUWKMLSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000005853 Clathrin Human genes 0.000 description 1
- 108010019874 Clathrin Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101100058504 Drosophila melanogaster Muted gene Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 101150086827 bloc1s5 gene Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000031154 cholesterol homeostasis Effects 0.000 description 1
- 229930193282 clathrin Natural products 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 108010018413 epidermal growth factor precursor Proteins 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000006674 lysosomal degradation Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229940016590 sarkosyl Drugs 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- ZNJHFNUEQDVFCJ-UHFFFAOYSA-M sodium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[Na+].OCCN1CCN(CCS(O)(=O)=O)CC1 ZNJHFNUEQDVFCJ-UHFFFAOYSA-M 0.000 description 1
- CSRCBLMBBOJYEX-UHFFFAOYSA-M sodium;2-morpholin-4-ylethanesulfonic acid;hydroxide Chemical compound [OH-].[Na+].OS(=O)(=O)CCN1CCOCC1 CSRCBLMBBOJYEX-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 210000003956 transport vesicle Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20241—Use of virus, viral particle or viral elements as a vector
- C12N2760/20245—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20261—Methods of inactivation or attenuation
- C12N2760/20262—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17306255 | 2017-09-22 | ||
| EP17306255.5 | 2017-09-22 | ||
| PCT/EP2018/075824 WO2019057974A1 (en) | 2017-09-22 | 2018-09-24 | GLYCOPROTEIN MUTATED FROM VESICULAR STOMATITIS VIRUS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3076094A1 true CA3076094A1 (en) | 2019-03-28 |
Family
ID=60153233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3076094A Pending CA3076094A1 (en) | 2017-09-22 | 2018-09-24 | Mutated glycoprotein of vesicular stomatitis virus |
Country Status (14)
| Country | Link |
|---|---|
| US (8) | US12091434B2 (enExample) |
| EP (3) | EP4446337A3 (enExample) |
| JP (2) | JP2020534007A (enExample) |
| CA (1) | CA3076094A1 (enExample) |
| DK (1) | DK3684786T3 (enExample) |
| ES (1) | ES2991089T3 (enExample) |
| FI (1) | FI3684786T3 (enExample) |
| HR (1) | HRP20241466T1 (enExample) |
| HU (1) | HUE069207T2 (enExample) |
| LT (1) | LT3684786T (enExample) |
| PL (1) | PL3684786T3 (enExample) |
| PT (1) | PT3684786T (enExample) |
| SI (1) | SI3684786T1 (enExample) |
| WO (1) | WO2019057974A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4446337A3 (en) * | 2017-09-22 | 2025-01-08 | Centre National de la Recherche Scientifique | Mutated glycoprotein of vesicular stomatitis virus |
| EP3708176A1 (en) * | 2019-03-15 | 2020-09-16 | Centre National De La Recherche Scientifique -Cnrs- | Mutant vsv ectodomain polypeptide and uses thereof |
| CA3140115A1 (en) | 2019-05-23 | 2020-11-26 | Massachusetts Institute Of Technology | Ligand discovery and gene delivery via retroviral surface display |
| EP4013459B1 (en) * | 2019-08-16 | 2025-07-23 | Mayo Foundation for Medical Education and Research | Chimeric vesiculoviruses and methods of use |
| JP2023509966A (ja) * | 2020-01-10 | 2023-03-10 | カロジェン コーポレイション | 腫瘍溶解性ウイルス様小胞の組成物および使用方法 |
| EP4100420A1 (en) * | 2020-02-06 | 2022-12-14 | Boehringer Ingelheim Vetmedica GmbH | Polypeptides useful for detecting anti-rhabdovirus antibodies |
| WO2022013872A1 (en) * | 2020-07-14 | 2022-01-20 | Ichilov Tech Ltd. | Pseudotyped viruses configured to express car in t-cells |
| EP4284821A1 (en) | 2021-01-27 | 2023-12-06 | Umoja Biopharma, Inc. | Lentivirus for generating cells expressing anti-cd19 chimeric antigen receptor |
| CN112852757A (zh) * | 2021-02-01 | 2021-05-28 | 南京大学 | 一种制备新型溶瘤病毒EM/VSV-G Ad5sPVRCD137L的方法 |
| US20240218390A1 (en) | 2021-02-26 | 2024-07-04 | Kelonia Therapeutics, Inc. | Lymphocyte targeted lentiviral vectors |
| BR112023021075A2 (pt) * | 2021-04-16 | 2023-12-12 | Massachusetts Inst Technology | Método para liberar um ou mais ácidos nucleicos a uma célula-tronco hematopoiética, e, método para edição de gene em uma célula-tronco hematopoiética |
| KR20240112950A (ko) * | 2021-12-06 | 2024-07-19 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 조작된 세포 진입에 의한 수용체-리간드 특이성의 발견을 위한 방법 및 조성물 |
| IL313473A (en) | 2021-12-15 | 2024-08-01 | Interius Biotherapeutics Inc | Pseudotyped viral particles, compositions comprising the same, and uses thereof |
| IL291148A (en) * | 2022-03-06 | 2023-10-01 | Noga Therapeutics Ltd | Lentiviral vectors for in vivo targeting of hematopoietic cells |
| AU2023272490A1 (en) | 2022-05-17 | 2024-12-12 | Umoja Biopharma, Inc. | Manufacturing viral particles |
| TW202409288A (zh) | 2022-07-25 | 2024-03-01 | 美商英特瑞斯生物療法公司 | 突變多肽、包含該等突變多肽之組合物及其用途 |
| WO2024050450A1 (en) | 2022-08-31 | 2024-03-07 | Gigamune, Inc. | Engineered enveloped vectors and methods of use thereof |
| WO2024098038A2 (en) | 2022-11-04 | 2024-05-10 | Umoja Biopharma, Inc. | Polynucleotide construct and related viral vectors and methods |
| WO2024098028A2 (en) | 2022-11-04 | 2024-05-10 | Umoja Biopharma, Inc. | Lentiviral particles displaying fusion molecules and uses thereof |
| WO2024097992A2 (en) | 2022-11-04 | 2024-05-10 | Umoja Biopharma, Inc. | Particles displaying adhesion-molecule fusions |
| KR20250160369A (ko) | 2023-01-27 | 2025-11-12 | 리제너론 파마슈티칼스 인코포레이티드 | 변형된 랩도바이러스 당단백질 및 이의 용도 |
| WO2024196738A2 (en) * | 2023-03-17 | 2024-09-26 | Kelonia Therapeutics, Inc. | In vivo daric |
| KR20250167052A (ko) * | 2023-04-10 | 2025-11-28 | 선전 제노큐리 바이오테크 컴퍼니 리미티드 | 돌연변이형 vsvg 및 표적화 벡터 |
| WO2024216227A1 (en) | 2023-04-12 | 2024-10-17 | Vyriad | Cd3-redirected vectors, components thereof, and uses of the vectors and components thereof |
| WO2024238153A1 (en) | 2023-05-15 | 2024-11-21 | Umoja Biopharma, Inc. | Lentiviral delivery of anti-cd20 chimeric antigen receptors |
| WO2025006882A1 (en) * | 2023-06-30 | 2025-01-02 | The Children's Hospital Of Philadelphia | Click chemistry assisted cell surface engineering for restoring lentivirus entry |
| WO2025017052A1 (en) * | 2023-07-18 | 2025-01-23 | Vivebiotech S.L. | Purification resin and methods for using the same |
| TW202521554A (zh) * | 2023-08-11 | 2025-06-01 | 美商克隆尼亞治療股份有限公司 | 用於修飾細胞的組成物 |
| WO2025036498A1 (zh) * | 2023-08-16 | 2025-02-20 | 深圳市济因生物科技有限公司 | 一种病毒载体及其在感染b细胞中的应用 |
| WO2025072257A1 (en) * | 2023-09-25 | 2025-04-03 | Kelonia Therapeutics, Inc. | Compositions for treating cancer |
| US12403194B2 (en) | 2023-09-25 | 2025-09-02 | Kelonia Therapeutics, Inc. | Compositions for treating cancer |
| US20250101122A1 (en) | 2023-09-25 | 2025-03-27 | Kelonia Therapeutics, Inc. | Antigen binding polypeptides |
| WO2025072615A1 (en) | 2023-09-29 | 2025-04-03 | Orbital Therapeutics, Inc. | Improved methods of making rna by splinted ligation and compositions thereof |
| WO2025102013A1 (en) | 2023-11-10 | 2025-05-15 | Vyriad | Rhabdovirus g proteins having one or more cysteine-rich regions and uses thereof |
| WO2025162379A1 (zh) * | 2024-02-01 | 2025-08-07 | 深圳市济因生物科技有限公司 | 一种多肽及包含所述多肽基因的病毒载体 |
| WO2025189142A1 (en) | 2024-03-08 | 2025-09-12 | Vyriad | Membraned vesicles and purification methods thereof |
| WO2025212851A2 (en) | 2024-04-03 | 2025-10-09 | Orbital Therapeutics, Inc. | mRNA COMPOSITIONS AND USES THEREOF IN VARICELLA ZOSTER VIRUS VACCINES |
| WO2025231174A1 (en) | 2024-04-30 | 2025-11-06 | Umoja Biopharma, Inc. | Manufacturing viral particles |
| WO2025231185A1 (en) | 2024-05-01 | 2025-11-06 | Legend Biotech Ireland Limited | Viral glycoprotein variants and uses thereof |
| WO2025235604A1 (en) | 2024-05-08 | 2025-11-13 | Umoja Biopharma, Inc. | Fusion protein for use as immune cell engager |
| WO2025259931A1 (en) | 2024-06-14 | 2025-12-18 | Orbital Therapeutics, Inc. | Compositions and methods for rna circularization |
| WO2025260074A1 (en) | 2024-06-14 | 2025-12-18 | Vyriad | Multiplexing functional polypeptides and recombinant rhabdoviral g glycoproteins on enveloped delivery vehicles |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1716858B9 (en) * | 1999-09-17 | 2009-08-12 | Wellstat Biologics Corporation | Oncolytic virus |
| NZ534492A (en) * | 2002-02-07 | 2009-10-30 | Novozymes Delta Ltd | Albumin-fused kunitz domain peptides |
| JP4411523B2 (ja) * | 2004-03-04 | 2010-02-10 | 株式会社日健総本社 | 抗ウイルス剤 |
| US8008268B2 (en) * | 2006-07-25 | 2011-08-30 | Merial Limited | Vaccines against vesicular stomatitis |
| AU2008285224B2 (en) * | 2007-08-03 | 2015-01-22 | Centre National De La Recherche Scientifique (Cnrs) | Lentiviral gene transfer vectors and their medicinal applications |
| EP2020444B1 (en) * | 2007-08-03 | 2017-05-31 | Institut Pasteur | Defective non-integrative lentiviral transfer vectors for vaccines |
| US9296790B2 (en) | 2008-10-03 | 2016-03-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for protein delivery |
| BR112015013669A2 (pt) * | 2012-12-12 | 2017-11-14 | Childrens Hospital Of Eastern Ontario Res Institute Inc | composições e métodos para o tratamento de cânceres cerebrais |
| EP4446337A3 (en) | 2017-09-22 | 2025-01-08 | Centre National de la Recherche Scientifique | Mutated glycoprotein of vesicular stomatitis virus |
-
2018
- 2018-09-24 EP EP24192417.4A patent/EP4446337A3/en active Pending
- 2018-09-24 HR HRP20241466TT patent/HRP20241466T1/hr unknown
- 2018-09-24 DK DK18773448.8T patent/DK3684786T3/da active
- 2018-09-24 JP JP2020516534A patent/JP2020534007A/ja active Pending
- 2018-09-24 US US16/649,271 patent/US12091434B2/en active Active
- 2018-09-24 FI FIEP18773448.8T patent/FI3684786T3/fi active
- 2018-09-24 EP EP24192413.3A patent/EP4442816A3/en active Pending
- 2018-09-24 LT LTEPPCT/EP2018/075824T patent/LT3684786T/lt unknown
- 2018-09-24 CA CA3076094A patent/CA3076094A1/en active Pending
- 2018-09-24 EP EP18773448.8A patent/EP3684786B1/en active Active
- 2018-09-24 HU HUE18773448A patent/HUE069207T2/hu unknown
- 2018-09-24 PT PT187734488T patent/PT3684786T/pt unknown
- 2018-09-24 PL PL18773448.8T patent/PL3684786T3/pl unknown
- 2018-09-24 SI SI201831168T patent/SI3684786T1/sl unknown
- 2018-09-24 ES ES18773448T patent/ES2991089T3/es active Active
- 2018-09-24 WO PCT/EP2018/075824 patent/WO2019057974A1/en not_active Ceased
-
2023
- 2023-08-28 JP JP2023138247A patent/JP2023179436A/ja active Pending
- 2023-09-25 US US18/473,720 patent/US12030915B2/en active Active
-
2024
- 2024-04-08 US US18/629,097 patent/US12269848B2/en active Active
- 2024-04-08 US US18/629,579 patent/US12291551B2/en active Active
- 2024-04-08 US US18/629,504 patent/US12264180B2/en active Active
- 2024-04-08 US US18/629,466 patent/US12297237B2/en active Active
-
2025
- 2025-02-14 US US19/053,784 patent/US12410215B2/en active Active
- 2025-02-14 US US19/053,808 patent/US12410216B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12291551B2 (en) | Mutated glycoprotein of vesicular stomatitis virus | |
| Kretzschmar et al. | Membrane association of influenza virus matrix protein does not require specific hydrophobic domains or the viral glycoproteins | |
| US12435111B2 (en) | Mutant VSV ectodomain polypeptide and uses thereof | |
| US12203092B2 (en) | Self-inactivating rabies virus vector encoding a nucleoprotein and degron | |
| US10596264B2 (en) | Peptides with viral infection enhancing properties and their use | |
| CN115003328A (zh) | 重组神经氨酸酶及其用途 | |
| HK40117176A (en) | Mutated glycoprotein of vesicular stomatitis virus | |
| HK40117175A (en) | Mutated glycoprotein of vesicular stomatitis virus | |
| US20150141617A1 (en) | Production and purification of active eukaryotic formylglycinegenerating enzyme (fge) variants | |
| ES2813827T3 (es) | Péptidos que incluyen un dominio de unión de la subunidad de la fosfoproteína (P) viral a la nucleoproteína (N0) libre de ARN viral | |
| WO2024018364A1 (en) | Enveloped virus like particles comprising sars-cov-2 s protein | |
| Risco Quiroz | Development of a Novel Strategy to Treat Spinal Muscular Atrophy | |
| NZ752808A (en) | Stabilized soluble prefusion rsv f polypeptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230920 |